Skip to main content
Premium Trial:

Request an Annual Quote

Cue Health: Josh Ghaim, Sachin Jain

Josh Ghaim and Sachin Jain have joined Cue Health's board of directors, the company said.

Ghaim joined the board in July and is the founder and managing partner of innovation accelerator Ignite Venture Studio. He was previously chief technology officer at Johnson & Johnson Consumer Health.

Jain joined the board last month and is president and CEO of Scan Group, as well as a professor of medicine at Stanford University. He previously served as CEO of CareMore and Aspire Health (subsidiaries of health insurance provider Elevance Health) and was chief medical information and innovation officer at pharmaceutical firm Merck. He was also an attending physician at Boston VA Medical Center and a faculty member at both Harvard Medical School and Harvard Business School. Jain has served in leadership roles at the US Department of Health and Human Services.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.